Stay updated on Pembrolizumab in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab in Glioblastoma Clinical Trial page
- Check4 days agoChange DetectedThe new screenshot shows an updated last update date (May 13, 2025) and minor formatting changes. There are no substantive changes to the study design, eligibility criteria, primary or secondary outcomes, or reported results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check33 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

- Check40 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check55 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed. This is a minor UI change with no impact on core content, pricing, stock, or time slot availability.SummaryDifference0.1%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.1%

- Check69 days agoChange DetectedThe web page has updated the facility name and location while removing several specific medical terms and classifications, including various drug categories and conditions.SummaryDifference2%

Stay in the know with updates to Pembrolizumab in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.